N-Power Medicine, a company focused on reinventing the clinical trial process, has successfully closed its Series B funding round, amassing a total of $72 Million in funding to date. This significant financial boost is spearheaded by the Merck Global Health Innovation Fund, with contributions from a US-based healthcare-focused investor. The investment is earmarked for broadening N-Power's network of oncology clinics and enhancing collaborations with biopharmaceutical companies through its innovative platform that integrates clinical research into routine patient care.
Mark Lee, M.D., Ph.D., Co-Founder and Chief Executive Officer of N-Power Medicine, highlighted the inefficiencies of the current clinical trial paradigm, emphasizing the lengthy process from drug development to market availability. N-Power's vision is to drastically reduce these timelines by enabling every oncologist and cancer patient to participate in drug development, thereby benefiting patients significantly.
Founded in 2021, N-Power Medicine has developed a pioneering integrated platform that offers a unified workflow for both clinical trials and routine patient management. This platform employs a 'human in the loop' model, combining virtual and on-site staff with AI-enabled workflow automation to assist oncologists in generating research-ready data and preparing standardized clinical documentation.
The company's platform is built around three core components: the Kaleido™ Registry, which collects real-time, standardized patient data for clinical trials and drug development; point of care technology that facilitates seamless workflow management and secure access to patient data; and on-site and virtual experts who support oncologists and research staff in operationalizing the Registry and reducing their workload.
David M. Rubin, Ph.D., Managing Director of the Merck Global Health Innovation Fund, praised N-Power's unique approach for expanding clinical research to more oncologists and patients through standardized data collection and actionable insights. Barbara L. McAneny, MD, FASCO, MACP, founder and CEO of the New Mexico Cancer Center, also commended N-Power's efforts in addressing major challenges faced by oncologists, including managing electronic medical records and finding patients for clinical trials.
N-Power Medicine's mission is to dramatically increase clinical trial participation to accelerate oncology drug development, thereby bringing life-saving innovations to cancer patients more swiftly. The company integrates technology and trained personnel into routine care to unlock the full potential of data needed for developing new therapies.
